Thermo Fisher Scientific's second quarter revenue grew 10% to $11.99 billion, beating estimates on 5% organic growth.

Thermo Fisher Scientific reported second quarter 2026 revenue of $11.99 billion, up 10% year-over-year, with adjusted EPS of $6.03, an increase of 13%. These results surpassed analyst expectations for both revenue and earnings, driven by strengthening end markets.

Key Highlights

• Organic revenue grew by 5%, outperforming expectations and indicating solid performance in the underlying business.
• Adjusted operating margin expanded to 22.8% from 21.9% in the same quarter last year, reflecting improved profitability.
• The company's largest segment, Laboratory Products and Biopharma Services, grew revenue 11.7% to $6.69 billion.
• Thermo Fisher returned $1.0 billion to shareholders through stock repurchases during the quarter.